Citadel Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-14,200
| Closed | -$23.7K | – | 13659 |
|
|
2025
Q4 | $23.7K | Sell |
14,200
-6,700
| -32% | -$11.6K | ﹤0.01% | 12298 |
|
|
2025
Q3 | $35.3K | Buy |
+20,900
| New | +$24.7K | ﹤0.01% | 12344 |
|
|
2025
Q2 | – | Sell |
-3,000
| Closed | -$1.35K | – | 13930 |
|
|
2025
Q1 | $1.35K | Buy |
+3,000
| New | +$1.76K | ﹤0.01% | 14144 |
|
|
2024
Q4 | – | Sell |
-1,000
| Closed | -$905 | – | 14994 |
|
|
2024
Q3 | $905 | Buy |
1,000
+600
| +150% | +$556 | ﹤0.01% | 13938 |
|
|
2024
Q2 | $399 | Buy |
+400
| New | +$442 | ﹤0.01% | 14004 |
|
|
2024
Q1 | – | Sell |
-900
| Closed | -$981 | – | 15082 |
|
|
2023
Q4 | $981 | Buy |
+900
| New | +$986 | ﹤0.01% | 13904 |
|
|
2023
Q3 | – | Sell |
-500
| Closed | -$705 | – | 14736 |
|
|
2023
Q2 | $705 | Hold |
500
| – | – | ﹤0.01% | 14060 |
|
|
2023
Q1 | $750 | Sell |
500
-1,000
| -67% | -$1.4K | ﹤0.01% | 14421 |
|
|
2022
Q4 | $1.75K | Buy |
+1,500
| New | +$1.89K | ﹤0.01% | 14421 |
|
|
2022
Q2 | – | Sell |
-13,400
| Closed | -$21K | – | 13555 |
|
|
2022
Q1 | $21K | Sell |
13,400
-500
| -4% | -$776 | ﹤0.01% | 13224 |
|
|
2021
Q4 | $34K | Sell |
13,900
-900
| -6% | -$2.11K | ﹤0.01% | 13424 |
|
|
2021
Q3 | $37K | Sell |
14,800
-27,800
| -65% | -$71.3K | ﹤0.01% | 13501 |
|
|
2021
Q2 | $121K | Buy |
42,600
+3,100
| +8% | +$8.02K | ﹤0.01% | 12735 |
|
|
2021
Q1 | $93K | Buy |
+39,500
| New | +$94.9K | ﹤0.01% | 12528 |
|
|
2019
Q2 | – | Sell |
-12,700
| Closed | -$17K | – | 9548 |
|
|
2019
Q1 | $17K | Buy |
+12,700
| New | +$15.8K | ﹤0.01% | 9092 |
|
|
2018
Q4 | – | Sell |
-15,088
| Closed | -$31K | – | 9484 |
|
|
2018
Q3 | $31K | Sell |
15,088
-30,975
| -67% | -$65.1K | ﹤0.01% | 8921 |
|
|
2018
Q2 | $83K | Buy |
46,063
+21,260
| +86% | +$42.8K | ﹤0.01% | 8312 |
|
|
2018
Q1 | $58K | Buy |
+24,803
| New | +$58.2K | ﹤0.01% | 7888 |
|
|
2016
Q1 | – | Sell |
-2,478
| Closed | -$8K | – | 7414 |
|
|
2015
Q4 | $8K | Sell |
2,478
-12,266
| -83% | -$36.7K | ﹤0.01% | 8337 |
|
|
2015
Q3 | $36K | Buy |
14,744
+3,097
| +27% | +$8.02K | ﹤0.01% | 7798 |
|
|
2015
Q2 | $34K | Buy |
11,647
+2,107
| +22% | +$8.17K | ﹤0.01% | 7885 |
|
|
2015
Q1 | $38K | Buy |
9,540
+7,434
| +353% | +$25.7K | ﹤0.01% | 7562 |
|
|
2014
Q4 | $6K | Sell |
2,106
-16,603
| -89% | -$44.9K | ﹤0.01% | 8240 |
|
|
2014
Q3 | $47K | Buy |
18,709
+17,346
| +1,273% | +$41.8K | ﹤0.01% | 6940 |
|
|
2014
Q2 | $3K | Sell |
1,363
-619
| -31% | -$1.4K | ﹤0.01% | 7795 |
|
|
2014
Q1 | $5K | Sell |
1,982
-5,576
| -74% | -$16.4K | ﹤0.01% | 7646 |
|
|
2013
Q4 | $22K | Buy |
7,558
+1,611
| +27% | +$4.87K | ﹤0.01% | 6406 |
|
|
2013
Q3 | $18K | Buy |
5,947
+5,575
| +1,499% | +$17.6K | ﹤0.01% | 6265 |
|
|
2013
Q2 | $1K | Buy |
+372
| New | +$1.19K | ﹤0.01% | 6441 |
|
Other funds holding LCTX
BC
VCM
DC
RA
AC
Citadel Advisors's LCTX Position: Q1 2026 in Review
Citadel Advisors reduced its Lineage Cell Therapeutics (LCTX) stake by 74% in Q1 2026, selling an estimated $634K and leaving 130,948 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #11348.
Citadel Advisors first reported a position in LCTX in Q2 2013 and has held it in 45 quarters since. The position peaked at $847K in Q4 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.
- Citadel Advisors held 130,948 shares of Lineage Cell Therapeutics worth $207K as of Q1 2026.
- Citadel Advisors sold 376,104 Lineage Cell Therapeutics shares in Q1 2026, an estimated $634K.
- Lineage Cell Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11348 holding.
- Citadel Advisors first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 45 quarters since.
- Citadel Advisors's Lineage Cell Therapeutics position peaked at $847K in Q4 2025.
- 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.